Navigation Links
Silence Therapeutics' Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
Date:3/29/2011

, Ph.D., chief executive officer of Silence Therapeutics.  

Silence expects to complete the ongoing Phase I clinical trial of Atu027 in the second half of 2011.  

Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a library of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration.  Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including reduced cytokine induction and decreased manufacturing costs.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The Company's lead internal drug candidate is Atu027, a liposomal AtuRNAi formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutics in the area of oncology. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as, repeated intravenous administration. The study is expected to be comp
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
2. Silence Therapeutics Provides Year-end Update
3. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
4. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
5. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
6. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
7. Silence Therapeutics Announces Board Changes
8. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
9. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
10. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
11. Osseon™ Therapeutics Introduces Osseoflex® BT Steerable Bone Tamp
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 Roche,s Bloodhound technology is ... segment in hematology testing, according to Kalorama Information.  ... unveiling of its Bloodhound digital cell imaging technology ... 511 hematology analyzer – is notable as ... by current leader CellaVision, but also compete more ...
(Date:7/2/2015)... DALLAS , July 2, 2015 ... Market by Technology (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial ... Trends & Global Forecast to 2020", published by MarketsandMarkets, the ... and is projected to reach $6.20 Billion by 2020, at ... Browse 8 4 market ...
(Date:7/2/2015)... , June 26, 2015 ... the "Vitamin D Market by Analog, Application, End-User & ... report to their offering. This market is projected ... of vitamin D in different applications and rising opportunities in ... China , Italy , and ...
Breaking Medicine Technology:Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3
... today announced the launch of the CELLTRACKS® Circulating Melanoma ... convenient and reliable way to capture CMCs for research ... CMCs, the CELLTRACKS® CMC kit is designed to offer ... based on a specific protein or mutation. ...
... May 24, 2011 TetraLogic Pharmaceuticals, a biopharmaceutical company ... announced that is has closed a $6 million investment ... based oncology focused venture capital fund.  Combined with the ... raised $43 million in the past year. The company ...
Cached Medicine Technology:Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Research Use 2Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Research Use 3TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd. 2TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd. 3TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd. 4
(Date:7/2/2015)... CITY, GA (PRWEB) , ... July 02, 2015 ... ... field sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the socks ... fitness experts and athletic trainers. Their significant popularity has inspired four new, fun ...
(Date:7/2/2015)... ... July 02, 2015 , ... Global leader and compression innovator, ... designed for men. , For style that’s quick on its feet, men will ... is great news for men everywhere because a simple change in socks can dramatically ...
(Date:7/2/2015)... ... , ... Six months ahead of his 80th birthday, Don Stevenson has reached ... for the Pulmonary Hypertension Association (PHA). Stevenson began the walk in Washington State ... mid-September. He left Glasgow, Mont. yesterday morning and is making his way to Wolf ...
(Date:7/2/2015)... , ... July 02, 2015 , ... The ZAC Foundation, ... 2015 swim season with important lessons on how to stay water safe with the ... Couldn’t, Wouldn’t Swim, authored by The ZAC Foundation co-founders, follows Zeke’s water safety journey. ...
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ActiveBunch.com ... a passion for social fitness. Built to function as a lifestyle community, Active Bunch ... them the opportunity to network, meet, and participate in discussions or group events. ...
Breaking Medicine News(10 mins):Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2
... explain the increased cases , FRIDAY, Nov. 6 (HealthDay News) ... people at higher risk of getting a type of thyroid ... related to cancer, but researchers suspect that the toxic compounds ... also unsure of why thyroid cancer rates are rising around ...
... motor skills later, study suggests, , THURSDAY, Nov. 5 ... at birth often go on to have lifetime disabilities, ... prevent problems. , Now, a new study reports that ... in the babies. , Oxygen starvation at birth ...
... Water has designated the week of November 9, 2009 as ... area as part of a national campaign sponsored by public ... pharmaceutical pollution in our source water supplies. , Sacramento County ... , , Household Hazardous Waste ...
... HeartWare International, Inc. (Nasdaq: HTWR ... less invasive, miniaturized circulatory support technologies revolutionizing the treatment ... scheduled to make presentations at two upcoming investor conferences ... at the Third Annual Canaccord Adams Cardiovascular Conference at ...
... ... procedure that allows almost anyone to sustain life in the first critical minutes ... enough to keep vital organs alive until professional rescuers arrive. AED (Automated External ... get to return to a normal heartbeat. AEDs are very accurate and easy ...
... ... Testing Recommendations Are Expected To Become A Law Very Soon For Commercial ... Apnea Lab Testing Could Cost About $2,000 With A Waiting Period Of ... Not Tolerate Standard CPAP Treatment. Dr. Jin Zhou Of SleepApneaUSA.net Proposed An ...
Cached Medicine News:Health News:Thyroid Cancer Higher in Volcanic Areas 2Health News:California American Water Celebrates 'No Drugs Down the Drain' Week in Sacramento 2Health News:HeartWare to Present at Upcoming Investment Conferences in November 2Health News:A New Era of E-Learning in the Comfort and Convenience of Your Home or Office Without the Classroom Environment 2Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 2Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 3Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 4Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 5
... Narkotron II is a comprehensive vital sign monitor. , ... quality, affordable products for efficiency in patient care., ... 2 - Temp - Multi-gas Sensor (HAL, ... )., ,Optional Functions: ,5-Lead ECG - FiO 2 ...
... monitor is a low-cost, multi-parameter monitor designed ... and surgery. The large display provides bright ... from across the room. The intuitive design ... the monitor in just minutes., ,Standard ...
... the features needed for quality, comprehensive portable ... color display allows you to see up ... ECG. The touch screen allows easy navigation ... gloves or temperature., ,Standard features include ...
... Compact all-in-one anesthesia monitor., ... monitor designed for use in the ... room and PACU. The Cardiocap/5 offers ... the monitoring of oxygenation and circulation ...
Medicine Products: